Naresh Singh, MD
Pulmonary Disease · Las Vegas, NVNPI 1790721116
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $95,282 of the $111,459 with a category attached, or 85.5%. 17 manufacturers reported payments, led by AstraZeneca at 39.1% of the total. Reporting peaked in 2019 at $36,030 and has fallen 67.9% since, to $11,559 in 2025. Among pulmonary disease clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 255 payments — averaging $437.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$44K
- Mylan Specialty L.p.$34K
- Grifols USA, LLC$19K
- Boehringer Ingelheim$10K
- Actelion Pharmaceuticals US, Inc.$1K
- Grifols Shared Services North America, Inc.$820
- plus $2K from 11 others
Across 92 payments — averaging $6514.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mylan Specialty L.p.$147K
- AstraZeneca$138K
- Chiesi USA, Inc.$134K
- Genentech, Inc.$130K
- Verona Pharma, Inc.$19K
- GSK$17K
- plus $14K from 1 others
What the payments were for
- Consulting fees$6,7126%
- Speaking & faculty fees$95,28285%
- Travel & lodging$1,4861%
- Food & beverage$7,4177%
- Education$5621%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 69 | $43,595 |
| Mylan Specialty L.p. | 71 | $34,253 |
| Grifols USA, LLC | 23 | $19,204 |
| Boehringer Ingelheim | 20 | $9,992 |
| Actelion Pharmaceuticals US, Inc. | 25 | $1,163 |
| Grifols Shared Services North America, Inc. | 1 | $820 |
| United Therapeutics Corporation | 7 | $546 |
| Melinta Therapeutics, LLC | 12 | $454 |
| Merck | 8 | $405 |
| Bayer | 3 | $341 |
| Johnson & Johnson | 3 | $322 |
| GSK | 6 | $115 |
| Intuitive Surgical | 1 | $98 |
| Paratek Pharmaceuticals, Inc. | 3 | $70 |
| Verona Pharma, Inc. | 1 | $52 |
| Insmed, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$38,367
- Yupelri$33,275
- Prolastin-C Liquid$15,203
- Prolastin-C$4,784
- BREZTRI AEROSPHERE$2,875
- BEVESPI AEROSPHERE$1,350
- Adempas$325
- XARELTO$300
- WINREVAIR$245
- UPTRAVI$145
- OPSUMIT$145
- OFEV$125
- ORENITRAM$125
- TYVASO$125
- Rezzayo$120
How this compares
$111,459 in reported general payments places this provider in the 95th percentile of 84 pulmonary disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 147 | $1,824,853 |
| OfevNintedanib Esylate | 131 | $1,800,052 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 114 | $1,286,915 |
| AdempasRiociguat | 57 | $752,421 |
| UptraviSelexipag | 24 | $589,856 |
| GlassiaAlpha-1-Proteinase Inhibitor | 12 | $241,403 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 267 | $240,261 |
| ZemairaAlpha-1-Proteinase Inhibitor | 13 | $190,197 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 174 | $157,807 |
| Spiriva RespimatTiotropium Bromide | 87 | $61,514 |
| Breo ElliptaFluticasone/Vilanterol | 98 | $51,343 |
| Orenitram ErTreprostinil Diolamine | 12 | $39,453 |
| Ambrisentan | 22 | $37,385 |
| Pirfenidone | 47 | $34,056 |
| SymbicortBudesonide/Formoterol Fumarate | 67 | $29,747 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $1,163 | $2,414,708171 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $9,992 | $1,889,525252 claims |
| Grifols USA, LLCProlastin C | $19,204 | $1,286,915114 claims |
| BayerAdempas | $341 | $752,42157 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $115 | $313,992411 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $12 | $241,40312 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $43,595 | $194,666256 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 84 pulmonary disease providers in Nevada.
Other pulmonary disease in Las Vegas
- Arthur RomeroLas Vegas$310K
- Lloyd DelmundoLas Vegas$150K
- Abhishek KumarLas Vegas$74K
- Jerome HruskaLas Vegas$72K
- Vishisht MehtaLas Vegas$22K
- Kamran KhanLas Vegas$17K
- John WojcikLas Vegas$14K
- Walter WilloughbyLas Vegas$10K
- Robert LampertLas Vegas$8K
- Rachakonda PrabhuLas Vegas$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.